Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockSermorelin
Third-Party TestedPurity Standards
Total
$29.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Type
Synthetic peptide (29 residues, C-terminal amide)
Molecular formula
C149H246N44O42S
Molecular weight
~3,358 g/mol
CAS number
86168-78-7
Amino acids
29
Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Modification
C-terminal amidation; sequence corresponds to residues 1-29 of human GHRH (the N-terminal fragment that retains intrinsic activity).
Mechanism & Target Class
Mechanism & Target Class
A synthetic 29-residue C-terminally amidated peptide corresponding to the N-terminal fragment (residues 1-29) of a 44-residue hypothalamic peptide - the minimal segment that retains the intrinsic structural activity of the longer parent. Solution NMR in a membrane-mimetic solvent describes substantial alpha-helical character, and cryo-EM of the peptide bound to its class B1 (secretin-like) G-protein-coupled receptor complex resolves a continuous alpha-helical conformation contacting the receptor extracellular domain, extracellular loops, and transmembrane helices. Binding is described by a two-domain ('two-step') model in which the peptide engages both the receptor extracellular domain and its transmembrane core. As a small unmodified peptide it carries a single oxidation-sensitive methionine and is characterized by rapid circulatory clearance, distinguishing it from chemically stabilized analogs bearing acyl or amino-acid-substitution modifications.
Storage & Handling
Storage & Handling
Lyophilized
20°C (-80°C long term)
powder protected from light, typically stable many months desiccated.
Avoid freeze-thaw; aliquot; protect from light and moisture. Contains an oxidation-sensitive methionine.
References
References
Reviews
- 1
Granata R, et al. (2025). Nat Rev Endocrinol
- 2
Montero-Hidalgo AJ, et al. (2025). Rev Endocr Metab Disord
Reviews
- 3
Walker RF. (2006). Clin Interv Aging
- 4
Lin-Su K, Wajnrajch MP. (2002). Rev Endocr Metab Disord
- 5
Prakash A, Goa KL. (1999). BioDrugs
Clinical
- 6
Baker LD, et al. (2012). Arch Neurol
- 7
Khorram O, et al. (1997). J Clin Endocrinol Metab
- 8
Vittone J, et al. (1997). Metabolism
- 9
Thorner M, et al. (1996). J Clin Endocrinol Metab
- 10
Corpas E, et al. (1992). J Clin Endocrinol Metab
- 11
ClinicalTrials.gov. ClinicalTrials.gov
Primary research
- 12
Zhou F, et al. (2020). Nat Commun
- 13
Kanashiro-Takeuchi RM, et al. (2012). Proc Natl Acad Sci USA
- 14
Kanashiro-Takeuchi RM, et al. (2010). Proc Natl Acad Sci USA
- 15
Godfrey P, et al. (1993). Nat Genet
- 16
Mayo KE. (1992). Mol Endocrinol
- 17
Theriault Y, et al. (1988). Biopolymers
- 18
Ling N, et al. (1984). Proc Natl Acad Sci USA
- 19
Rivier J, et al. (1982). Nature
- 20
Guillemin R, et al. (1982). Science
Primary Database
Primary Database
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
